Cryo Cell International Inc (CCEL) Stock Price & Analysis
Cryo Cell International Inc (CCEL) fell 5.99% to USD 3.45 as of June 10, 2026 at 02:34 UTC, according to Nexqual real-time market data.
CCEL last closed at USD 3.67; the session ranged USD 3.45–3.45 on volume of 2,258 shares. Market capitalization is $27.79M, with a 52-week range of USD 2.72–6.35 (ASE). Source: Nexqual, June 10, 2026 at 02:34 UTC.
Key Statistics (as of June 10, 2026 at 02:34 UTC)
| Price | USD 3.45 |
|---|---|
| Change | ▼ 5.99% (down) |
| Previous Close | USD 3.67 |
| Open | USD 3.45 |
| Day Range | USD 3.45 – 3.45 |
| 52-Week Range | USD 2.72 – 6.35 |
| Volume | 2,258 shares |
| Market Cap | $27.79M |
| Exchange | ASE |
Technical Analysis (CCEL)
Nexqual's technical model rates CCEL "BUY" based on 5 bullish and 1 bearish signals across 123 daily candles, as of June 10, 2026 at 02:34 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 55.36 (neutral) |
| vs SMA50 | Below (USD 3.54) |
| MACD | 0 (positive) |
Analyst Ratings (CCEL)
Wall Street analysts rate CCEL "None", per Nexqual as of June 10, 2026 at 02:34 UTC.
| Consensus Rating | None |
|---|---|
| Buy / Hold / Sell | 0 / 1 / 0 |
Earnings (CCEL)
| EPS Estimate | USD 0 |
|---|---|
| Revenue Estimate | $7.55M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-02-28 | USD 0.02 vs est -0.02 ▲ beat |
| 2025-11-30 | USD -0.47 vs est -0.09 ▼ miss |
| 2025-08-31 | USD 0.1 vs est -0.03 ▲ beat |
| 2025-05-31 | USD 0.05 vs est -0.04 ▲ beat |
Source: Nexqual, June 10, 2026 at 02:34 UTC.
Financials & Fundamentals (CCEL)
| Total Revenue | $31.28M |
|---|---|
| Revenue Growth (YoY) | -3.60% |
| Gross Margin | +63.53% |
| Operating Margin | +9.96% |
| Profit Margin | -8.52% |
| Current Ratio | 0.62 |
| Total Cash | $2.90M |
| Total Debt | $10.71M |
| Free Cash Flow | $159,919 |
Source: Nexqual, June 10, 2026 at 02:34 UTC.
Financial Health Score (CCEL)
Nexqual rates Cryo Cell International Inc's overall financial health "Weak" across five dimensions, as of June 10, 2026 at 02:34 UTC.
| Growth | Weak — Revenue -1% YoY (annual), declining |
|---|---|
| Profitability | Weak — Small revenue base — building scale |
| Balance Sheet | Mixed — $3M cash vs $11M debt |
| Cash Flow | Mixed — FCF $160K, slim 0.5% margin |
| Efficiency | Mixed — No data |
Ownership (CCEL)
| Insider Ownership | +42.07% |
|---|---|
| Institutional Ownership | +11.96% |
| Shares Outstanding | 8.06M |
| Float | 4.17M |
| Short % of Float | +0.28% |
Source: Nexqual, June 10, 2026 at 02:34 UTC.
Leadership (CCEL)
Cryo Cell International Inc is led by David I. Portnoy (age 62), Chairman & Co-CEO, per Nexqual as of June 10, 2026 at 02:34 UTC.
| Chairman & Co-CEO | David I. Portnoy (age 62) |
|---|---|
| Co-CEO & Director | Mark L. Portnoy (age 61) |
| CFO & VP of Finance | Jill M. Taymans (age 55) |
| Medical Director and Member of Medical & Scientific Advisory Board | Joanne Kurtzberg |
Major Backers & Investors (CCEL)
Notable institutional backers of Cryo Cell International Inc include SFI Advisors, LLC, MassMutual Private Wealth & Trust, FSB, Fidelity, according to Nexqual as of June 10, 2026 at 02:34 UTC.
Active Investors
| Investor | Stake |
|---|---|
| SFI Advisors, LLC | 1.46% |
| MassMutual Private Wealth & Trust, FSB | 0.98% |
| Fidelity | 0.32% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 3.07% |
| Geode Capital | 0.39% |
| BlackRock | 0.24% |
Source: Nexqual, June 10, 2026 at 02:34 UTC.
From Cryo Cell International Inc's Latest SEC 10-K Filing (filed 2026-02-27)
Key Strengths & Strategy (as disclosed to the SEC)
- Cryo-Cell International, Inc. engages in cord blood and cord tissue cryopreservation services in the United States.
- The company offers cellular processing and cryogenic storage for family use, primarily for collection and preservation of umbilical cord blood, and tissue stem cells; and cellular processing and cryogenic storage of umbilical cord blood stem cells for public use.
- It is also involved in the manufacturing of PrepaCyte CB processing system units for processing umbilical cord blood stem cells.
- In addition, the company provides cold storage services to third-party pharmaceutical companies and medical institutions.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| MCET | MULTICELL TECHNOLOGIES INC | USD 0 | ▲ 0% |
| SOTK | Sono-Tek Corporation | USD 5.23 | ▲ 2.35% |
| AOLS | AEOLUS PHARMACEUTICALS INC | USD 0 | ▲ 0% |
| ISCO | International Stem Cell Corp. | USD 0.17 | ▼ 5.56% |
| CSBR | Champions Oncology, Inc. | USD 5.79 | ▲ 2.48% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 02:34 UTC. This page is informational and not investment advice.